Table 2 Tumor markers of the study participants
|  | RA-no ILD (n = 135) | RA-indeterminate ILD (n = 107) | RA-mild ILD (n = 91) | RA-advanced ILD (n = 24) | RA-ILD (RA-mild ILD + RA-advanced ILD) (n = 115) | |
|---|---|---|---|---|---|---|
CA125,U/ml | 9.10(6.73,12.95) | 8.90(6.55,12.50) | 9.10(6.45,13.95) | 18.90(10.35,30.75)*** | 10.65(7.00,17.30) | |
CA153,U/ml | 6.40(4.68,10.50) | 7.05(5.60,10.90) | 8.00(4.80,12.70)* | 20.30(15.40,30.10)*** | 10.35(6.08,17.23)*** | |
CA19-9,U/ml | 14.16(8.66,21.02) | 15.25(9.21,22.97) | 16.57(10.54,25.28) | 26.43(11.68,73.37)* | 17.48(10.57,28.00)* | |
CA242,IU/ml | 3.68(2.64,5.86) | 3.25(2.29,5.69) | 4.27(3.07,6.28) | 3.99(2.21,25.37) | 4.25(3.03,6.58) | |
CA50,U/ml | 4.75(2.81,7.73) | 4.78(2.96,8.44) | 5.89(4.04,10.52)* | 7.04(4.63,16.75) | 6.54(4.06,10.65)* | |
CA724,U/ml | 1.47(0.89,3.24) | 1.93(0.92,3.47) | 1.58(0.94,3.26) | 2.05(1.14,5.42) | 1.61(0.94,3.53) | |
CEA, ng/ml | 0.95(0.50,1.50) | 0.99(0.50,1.61) | 1.32(0.51,1.90) | 1.37(1.17,2.87)** | 1.34(0.64,1.95)* | |
CYFRA21-1,ng/ml | 2.14(1.54,2.97) | 2.13(1.66,2.97) | 2.53(1.74,3.67)* | 3.70(2.49,5.77)*** | 2.71(1.91,4.31)*** | |
NSE, ng/ml | 3.11(2.56,3.98) | 3.19(2.43,4.08) | 3.39(2.72,4.49) | 4.30(3.41,5.38)** | 3.59(2.78,4.62) | |
proGRP, pg/ml | 30.99(23.33,43.67) | 34.90(26.46,45.63) | 34.13(27.62,46.30) | 32.96(18.99,43.40) | 34.13(25.16,45.15) | |
SCCA, ng/ml | 1.03(0.69,1.59) | 0.91(0.63,1.36) | 1.02(0.67,1.52) | 1.36(0.96,1.73) | 1.11(0.69,1.53) | |
KL-6,U/ml | 229.00(163.00,311.00) | 185.00(161.00,268.00) | 248.00(154.50,338.00) | 1190.50(654.25,1637.00)*** | 287.00(167.00,531.00) | |